

**Europass  
Curriculum Vitae****Personal information**First name(s) / Surname(s) **Laura Ancuta Pop**E-mail(s) [laura.ancuta.pop@gmail.com](mailto:laura.ancuta.pop@gmail.com), laura.pop@umfcluj.ro

Nationality Romanian

Gender Female

Desired employment /  
Occupational field **Researcher****Work experience**Occupation or position held **PhD Student**

Main activities and responsibilities Stereoselective chemoenzymatic synthesis of different bio-active substances. Chemical synthesis of some substances using organometallic catalysis. Performing substance analysis by HPLC, GC, GS-MS, NMR and elemental analysis. Interpreting MS, IR, NMR spectra. Writing PhD papers and articles. Participating to different international conferences.

Name and address of employer "Babes Bolyai" University, Faculty of Chemistry and Chemical Engineering Arany Janos Street no.11, 400028 Cluj Napoca (Romania) and INSA de Rouen Avenue de l'Université 76800 Saint-Étienne-du-Rouvray, France

Type of business or sector Education

Dates 10/2009 - 06/2010

Occupation or position held PhD Student internship

Main activities and responsibilities Chemical synthesis of new substances by organometallic catalysis. NMR analysis of these substances. NMR, IR, MS spectra interpretation. Participation to seminary and conferences.

Name and address of employer Institut de Recherche en Chimie Organique Fine Tesnière street, Mont Saint Aignan, 76130 Rouen (France)

Type of business or sector Research and education

Dates 03/2012-02/2014

Occupation or position held Postdoctoral position

Main activities and responsibilities	Extraction of DNA and RNA from blood, tissues and cell cultures; performing ELISA tests, Western Blot analysis, PCR and RT-PCR, cDNA synthesis, NextGen sequencing, cell cultures. Writing scientific article and grant proposal and participating to scientific conferences.
Name and address of employer	University of Medicine and Pharmacy ‘Iuliu Hatieganu’ , Victor Babes nr.8 Cluj Napoca Romania
Type of business or sector	Research and Education
Dates	03/2013-01.10.2015
Occupation or position held	Chemist
Main activities and responsibilities	Extraction of DNA and RNA from blood, tissues and cell cultures; performing ELISA tests, Western Blot analysis, PCR and RT-PCR, cDNA synthesis, NextGen sequencing, cell cultures. Writing scientific article and grant proposal and participating to scientific conferences
Name and address of employer	Iuliu Hatieganu, University of Medicine and Pharmacy, Research Center for Functional Genomics, Bimedicine and Translational Medicine, Cluj-Napoca
Type of business or sector	Research
Dates	01.10.2015-10.01.2018
Occupation or position held	Scientific Researcher
Main activities and responsibilities	Using next generation sequencing for clinical diagnosis, proteomic validation study, establishing proteomic signature in relation to functional genomics studies. <ol style="list-style-type: none"> <li>1. Establishing sample collection and processing protocols</li> <li>2. DNA extraction from biological samples</li> <li>3. Amplicon Library preparation and quantification, template synthesis, and sequencing.</li> <li>4. Sequencing data analysis using Ion Reporter and Variant Caller</li> <li>5. Identification of the molecular mechanisms that are altered based on the analysis of sequencing and bioinformatics data.</li> <li>6. Experimental data dissemination</li> <li>7. LC/MS data analyses protocols for protein profile identification</li> <li>8. Data analysis.</li> </ol>
Name and address of employer	University of Medicine and Pharmacy ‘Iuliu Hatieganu’ , Victor Babes nr.8 Cluj-Napoca Romania
Type of business or sector	Research and Education
Type of business or sector	Research
Dates	15.01.2018-present
Occupation or position held	Scientific Researcher III

Main activities and responsibilities	Using next generation sequencing for clinical diagnosis, proteomic validation study, establishing proteomic signature in relation to functional genomics studies. <ul style="list-style-type: none"> <li>• High throughput technologies applications in genetics for diagnosis and treatment evaluation of different diseases</li> <li>• Identification of new biomarkers with roles in diagnosis, prognosis and treatment for different diseases using next generation sequencing.</li> <li>• Analysis of sequencing data</li> <li>• Participation at national and international grant competitions.</li> <li>• Results dissemination in ISS journals with high impact factor.</li> </ul>
Name and address of employer	University of Medicine and Pharmacy ‘Iuliu Hatieganu’ , Victor Babes nr.8 Cluj-Napoca Romania
Type of business or sector	Research and Education
Type of business or sector	Research
<b>Education and training</b>	
Dates	1999 - 2003
Title of qualification awarded	College diploma
Principal subjects / occupational skills covered	Foreign languages (English and French), mathematics, physics, chemistry, biology, Romanian language, informatics, geography and history.
Name and type of organisation providing education and training	"Liviu Rebreanu" National Collage (Theoretical Collage) Republic Boulevard no.8, 420057 Bistrita (Romania)
Level in national or international classification	ISCED 4
Dates	2003 - 2007
Title of qualification awarded	Bachelor in Chemistry
Principal subjects / occupational skills covered	Mathematics, general chemistry, physics, analytical chemistry, English language, foreign language (French), physical education, psychology, inorganic chemistry, organic chemistry, pedagogy, biochemistry, technological chemistry, organometallic chemistry, methodology of teaching chemistry, material chemistry, food and pharmaceutical product analysis, biologically active compounds.
Name and type of organisation providing education and training	"Babes Bolyai" University (Faculty of Chemistry and Chemical Engineering) Arany Janos Street, no.11, 400028 Cluj Napoca (Romania)
Level in national or international classification	ISCED 5
Dates	2007 - 2008
Title of qualification awarded	Master in cellular biotransformation
Principal subjects / occupational skills covered	Advances enzymology, recombinant DNA technology, biochemical cellular signalling, optical and electron microscopy techniques, bioinformatics, selective biotransformation, industrial bioprocesses, applied

	biotransformation in food, pharmaceutical and organic industry, cell culture.									
Name and type of organisation providing education and training	"Babes Bolyai" University (Faculty of Biology and Geology) Gheorghe Bilascu street no.44, 400015 Cluj Napoca (Romania)									
Level in national or international classification	ISCED 6									
Dates	2008 - 2011									
Title of qualification awarded	PhD in Chemistry									
Principal subjects / occupational skills covered	<p>Mass spectroscopy, X ray diffraction and NMR in organometallics and organic chemistry, asymmetric synthesis, stereochemistry, enzymatic biotransformation in organic chemistry, enzymatic reaction mechanisms in enzymology.</p> <p>Scientific skills: Synthesis of non natural amino acids, resolution of non natural amino acids using enzymes.</p> <p>Synthesis and resolution of secondary hetero-aromatic alcohols, heterocyclic chemistry.</p> <p>Organometallic synthesis of several secondary thiazole alcohols.</p> <p>Cellular and enzymatic bioprocesses.</p> <p>Technical skills: 1H and 13C RMN, chromatographic methods (HPLC, GC), GC-MS.</p>									
Name and type of organisation providing education and training	"Babes Bolyai" University (Faculty of Chemistry and Chemical Engineering) Arany Janos stree no.11, 400028 Cluj Napoca (Romania) and INSA de Rouen Avenue de l'Université 76800 Saint-Étienne-du-Rouvray, France									
Level in national or international classification	ISCED 6									
<b>Personal skills and competences</b>										
Mother tongue(s)	<b>Romanian</b>									
Other language(s)										
Self-assessment	Understanding				Speaking				Writing	
<i>European level (*)</i>	Listening		Reading		Spoken interaction		Spoken production			
English	C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user
French	B2	Independent user	B2	Independent user	B1	Independent user	B1	Independent user	A1	Basic user
German	A1	Basic User	A1	Basic User	A1	Basic User	A1	Basic User	A1	Basic User
	(*) <a href="#"><i>Common European Framework of Reference (CEF) level</i></a>									

<b>Social skills and competences</b>	Communicative, eager to learn, adaptable, capable of working in a team, professionalism. Good ability to adapt to multicultural environment gained through my internship experience abroad.
<b>Organisational skills and competences</b>	Good experience in projects gained by teaching students practical laboratories.
<b>Technical skills and competences</b>	<p>Synthesis of non natural amino acids, resolution of non natural amino acids using enzymes gained by training and work.</p> <p>Synthesis and resolution of secondary hetero-aromatic alcohols, heterocyclic chemistry gained by training and work.</p> <p>Cellular and enzymatic bioprocesses gained by training.</p> <p>Competences of biocatalysis.</p> <p>Organometallic synthesis of several secondary thiazole alcohols gained by work.</p> <p><sup>1</sup>H and <sup>13</sup>C RMN, chromatographic methods (HPLC, GC), GC-MS gain by training and work.</p> <p>DNA and RNA extractions and quantification from blood, tissue and cell cultures.</p> <p>Performing different experiment: ELISA, PCR, RT-PCR, and Western Blot, LC-MS/MS and next generation sequencing.</p> <p>Knowledge on cell cultures, flowcytometry cDNA synthesis.</p> <p>Interpretation of electropherogram, NanoDrop spectra, RT-PCR amplification curves, ELISA and Western Blot data, MS, HPLC, LC-MS and RMN spectras.</p> <p>Performing NexGen Sequencing. NGS library preparation and quantification, template synthesis, sequencing and data interpretation.</p>
<b>Computer skills and competences</b>	<p>Good command of Microsoft office tools (Word, Excel, Power Point)</p> <p>Basic knowledge of statistical programs (Statistica, Prism5, )</p> <p>Good command of chemistry programs (ChemDraw, ChemWin, Topspin, Mestrec, Scifinder).</p> <p>Good knowledge of NGS data analysis Ion Reporter, Galaxy.</p>
<b>Member in International Organizations</b>	1. European Association of Cancer Research
<b>Driving license(s)</b>	B
<b>International Conferences</b>	<ul style="list-style-type: none"> <li>- “Cancer molecular Pathobiology in the clinics: Highlights, 18<sup>th</sup>-20<sup>th</sup> of April 2012, Cluj-Napoca, Romania.</li> <li>- International Workshop „Molecular Profiling and Innovation in Cancer” organized by UMF „Iuliu Hatieganu” Cluj-Napoca 10-12 September 2012</li> <li>- National Congress of Medical Oncology and Radiotherapy 2012 Cancer therapy in 2012: From a multidisciplinary approach to personalized therapy</li> <li>- “Mass spectrometry in Proteomics” Course, 10-14 December 2012,</li> </ul>

	<p>Biomedical Center, Lund University, Lund, Sweden.</p> <ul style="list-style-type: none"> <li>- Certificate of training for GJ Junior workflow and software package, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, 01-04.04.2013</li> <li>- International Conference “45 Years of Comparative Oncology in Romania”, 28 November-01 December 2013, Faculty of Veterinary Medicine of Bucharest, Romania with the oral presentation ”Ion Torrent sequencer as a promising tool for breast and cervical cancer diagnosis”</li> <li>- Seminary ”Strategies for Using IEEE Xplore, Open Access, How to publish” Technical University Cluj-Napoca and IEEE Publishing 14 May 2014.</li> <li>- European Human Genetics Conference 2014, May 31- June 3 in Milan, Italy with the poster ”<i>Mutation analysis of triple negative breast cancer patients using next generation sequencing</i>”</li> <li>- OECI 2014- Oncology days 12 June 2014, Cluj-Napoca, Romania with the oral presentation ”Analiza Mutatiilor Prezente la Paciente cu Cancer de Sân Triplu Negativ Folosind Secvențierea de Noua Generație”</li> <li>- Zilele Institutului Oncologic ”Prof. Dr. Ion Chiricuta” 13-14 June 2014, Cluj-Napoca, Romania with the poster ”<i>Mutation analysis of triple negative breast cancer patients using next generation sequencing</i>”</li> <li>- Scientific Writing Workshop organized by Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca and BioScience Writing, 18 June 2014 Cluj-Napoca, Romania.</li> <li>- OECI-EACR- Conference- Precision Medicine Conference, 1-4 March 2015, Numunster Abbey, Luxembourg with the poster: Triple Negative Breast Cancer Mutation Evaluation using Next Generation Sequencing</li> <li>- Breast Cancer (BRCA) Challenge Conference, 12-13-June-2015, Unesco Center, Paris, France</li> <li>-WIN symposium 2015, 29-30 June 2015, Paris, France with the poster entitle: Next Generation for BRCA1/2 mutation detection in triple negative breast cancer patients.</li> <li>- Workhopul Bioetical approaches &amp; Responsible conduct in Translational Research, 24-25.09.2015, Cluj-Napoca organized by USAMV as participant</li> <li>- Participation to the course Nanopharmacology in leukemia chemotherapy, 25.09.2015- The Oncology Institute ”Prof. Dr. I. Chiricuta”, Cluj-Napoca, Romania.</li> <li>- 1st Ovarian Cancer Academy, 04-07.10.2015 Cluj-Napoca as invited speaker with the oral presentation: Mutation Analysis in ovarian cancer. Romania Perspective.</li> <li>- Asco Conference: Alexandru Eniu, <u>Nicoleta Antone</u>, Andrei Stoian, Nora Dronca, Ramona Matei, Marjolijn Ligtenberg, Hicham Ouchene, Rares Eniu, Laura Pop "<i>BRCA 1/2 mutations by next-generation sequencing testing in 200 Romanian high-risk patients with breast cancer</i>", J Clin Oncol 35, 2017 (suppl; abstr e13116).</li> </ul>
ISI Articles	<ol style="list-style-type: none"> <li>1. <u>Pop L.A.</u>, Czompa A., Paizs C., Tosa M.I., Vass E., Mátyus P., Irimie F.D., Lipase catalyzed synthesis of both enantiomers of 3-chloro-1-phenylpropan-1-ols, <i>Synthesis-Stuttgart</i>, 2011, 18, 2921-2928. IF 2.5</li> </ol>

2. Pop L.A., Biocatalytic preparation of enantiopure 2-amino-3-(5-aryl-furan-2-yl) propanoic acids, *Stud. Univ. Babes-Bol.*, 2011, *LVI*, 155-166. IF 0.089
3. Pop L., Lassalas P., Bencze L.C., Toşa M.I., Nagy B., Irimie F.D., Hoarau C., Chemoenzymatic synthesis of highly enantiomerically enriched secondary alcohols with a thiazolic core, *Tetrahedron: Asymmetry*, 2012, *23*, 474-481. IF 2.115
4. Pop L.A., Puscas E, Pileczki V, Cojocneanu-Petric R, Braicu C, Achimas-Cadariu P, Berindan-Neagoe I. Quality control of Ion Torrent sequencing library. *Cancer Biomarkers* 2014;14(2-3):93-101. doi: 10.3233/CBM-130358. IF 0.972
5. Braicu C., Berindan-Neagoe I., Pileczki V., Cojocneanu-Petric R., Pop L.-A., Puscas E., Irimie A., Buiga R. Breast Tumor Bank: an important resource for developing translational cancer research in Romania. *Cancer Biomarkers*, 2014, *4*, 119-127, IF 0.972
6. Balacescu O., Balacescu L., Tudoran O., Todor N., Rus M., Buiga R., Susman S., Fetica B., Pop L., Maja L., Visan S., Ordeanu C., Berindan-Neagoe I., Nagy V. Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failure. *BMC Cancer*, 2014, *14*, 246. IF 3.33.
7. Tudoran O., Soritau O., Balacescu L, Pop L.A., Meurice G, Visan S, Balacescu O, Neagoe I. "PDGF beta targeting in cervical cancer cells reveals a fine tuning of compensatory signaling pathways that maintain autocrine stimulation", *J Cell Mol Med.* 2014 Oct 14. doi: 10.1111/jcmm.12449, IF 3.698
8. Tudoran O. M., Virtic O, Balacescu L., Pop L., Dragla F., Eniu A., Fetica B., Balacescu O., Berindan-Neagoe I. "Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients". *PLoS One.* 2014, *9(7):e102764.* doi: 10.1371/journal.pone.0102764 IF 3.534
9. Ionescu C, Braicu C, Chiorean R., Cojocneanu Petric R, Neagoe E., Pop L., Chira S., Ioana Berindan-Neagoe TIMP-1 expression in human colorectal cancer is associated with SMAD3 gene expression levels: a pilot study, *Journal of Gastrointestinal and Liver Diseases*, 2014, *23(4):413-420.* I.F. 1.849
10. Gherman C, Matea C T, Bele C, Tabaran F, Razvan S, Bindea M, Sergiu C, Braicu C, Pop L., Cojocneanu Petric R, Berindan-Neagoe I. Pharmacokinetics Evaluation of Carbon Nanotubes Using FTIR Analysis and Histological Analysis. *Journal of Nanoscience and Nanotechnology* 2015, *15*, 2865-2869. I.F 1.339
11. Braicu C, Pileczki V, Pop L, Petric RC, Chira S, Pointiere E, Achimas-Cadariu P, Berindan-Neagoe I. Dual Targeted Therapy with p53 siRNA and Epigallocatechingallate in a Triple Negative Breast Cancer Cell Model. *PLoS One.* 2015 Apr 7;10(4):e0120936. doi: 10.1371/journal.pone.0120936. eCollection 2015. IF 3.056
12. Petric RC, Braicu C, Bassi C, Pop L, Taranu I, Dragos N, Dumitrascu

- D, Negrini M, Berindan-Neagoe I. Interspecies Gene Name Extrapolation-A New Approach. PLoS One. 2015 Sep 25;10(9):e0138751. doi: 10.1371/journal.pone.0138751. eCollection 2015. IF 3.056
13. Bencze, LC, Komjati, B, Pop, LA, Paizs, C, Irimie, FD, Nagy, J, Poppe, L, Tosa, MI. Synthesis of enantiopure L-(5-phenylfuran-2-yl)alanines by a sequential multienzyme process. TETRAHEDRON-ASYMMETRY. 15 Oct 2015. 26 (18-19); 1095-1101 FI 2.155
14. Zaharie, Florin; Muresan, Mihai Stefan; Petrushev, Bobe; Berce, Cristian; Gafencu, Grigore-Aristide; Selicean, Sonia; Jurj, Ancuta; Cojocneanu-Petric, Roxana; Lisencu, Cosmin-Ioan; Pop, Laura-Ancuta; Pileczki, Valentina; Eniu, Dan; Muresan, Mihai-Andrei; Zaharie, Roxana; Berindan-Neagoe, Ioana; Tomuleasa, Ciprian; Irimie, Alexandru. Exosome-Carried microRNA-375 Inhibits Cell Progression and Dissemination via Bcl-2 Blocking in Colon Cancer. Journal of gastrointestinal and liver diseases. 2015-Dec, 24(4); 435-443. FI 2.202
15. Ovidiu Balacescu, Loredana Balacescu, Oana Virtic, Simona Visan, Claudia Gherman, Flaviu Drigla, Laura Pop, Gabriela Bolba-Morar, Carmen Lisencu, Bogdan Fetica, Oana Tudoran, and Ioana Berindan-Neagoe. Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients, Mediators of Inflammation. 2016, Article ID 3239167, 12 pages FI 3.232
16. Laura A Pop, Valentina Pileczki, Roxana M Cojocneanu-Petric, Bogdan Petrut, Cornelia Braicu, Ancuta M Jurj, Rares Buiga, Patriciu Achimas-Cadariu, Ioana Berindan-Neagoe, Normalization of Gene Expression Measurement of Tissue Samples obtained by transurethral resection of bladder tumors, Oncotarget and Therapy, 2016, 9, 3369-3380. IF 1.653
17. SANDA BOCA, CIPRIAN LUCAN, IOANA FRINC, BOBE PETRUSHEV , TIMEA SIMON, CRISTIAN BERCE, GRIGORE-ARISTIDE GAFENCU, DELIA DIMA, ALINA TANASE, SONIA SELICEAN, VALENTINA PILECZKI, LAURA POP, VLAD MOISOIU, ANCA BUZOIANU, ADRIAN FLOREA, ALEXANDRU IRIMIE, SIMION ASTILEAN, ANCA BOJAN, IOANA BERINDAN-NEAGOE, CIPRIAN TOMULEASA, GOLD NANOPARTICLES CONJUGATED WITH RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA, FARMACIA, 2016, Vol. 64, 5, 688-698. IF 1.348
18. Pileczki V, Pop L, Braicu C, Budisan L, Bolba Morar G, Del C Monroig-Bosque P, Sandulescu RV, Berindan-Neagoe I. Double gene siRNA knockdown of mutant p53 and TNF induces apoptosis in triple-negative breast cancer cells. Onco Targets Ther. 2016 Nov 11;9:6921-6933. IF 1.653
19. Tomuleasa C, Selicean S, Gafencu G, Petrushev B, Pop L, Berce C, Jurj A, Trifa A, Rosu AM, Pasca S, Magdo L, Zdrenghia M, Dima D, Tanase A, Frinc I, Bojan A, Neagoe IB, Ghiaur G, Ciurea SO. Fibroblast Dynamics as an In Vitro Screening Platform for Anti-fibrotic Drugs in Primary Myelofibrosis. J Cell Physiol. 2018 Jan;233(1):422-433. doi:



- 10.1002/jcp.25902. Epub 2017 May 23. IF 1.193
20. Tomuleasa C, Zaharie F, Muresan MS, Pop L, Fekete Z, Dima D, Frinc I, Trifa A, Berce C, Jurj A, Berindan-Neagoe I, Zdrenghea M. How to Diagnose and Treat a Cancer of Unknown Primary Site. *J Gastrointest Liver Dis.* 2017 Mar;26(1):69-79. doi: 10.15403/jgld.2014.1121.261 IF 1.837
21. Tirinescu DC, Tomuleasa C, Pop L, Bondor CI, Vlăduțiu DȘ, Pațiu IM, Rusu CC, Moldovan DT, Potra A, Kacsó IM. Matrix-Metalloproteinase-2 Predicts Arteriovenous Fistula Failure in Hemodialysis Patients. *Ther Apher Dial.* 2017 Dec;21(6):586-591. doi: 10.1111/1744-9987.12584. Epub 2017 Sep 3.
22. Braicu OL, Budisan L, Buiga R, Jurj A, Achimas-Cadariu P, Pop LA, Braicu C, Irimie A, Berindan-Neagoe I. miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples. *OncoTargets Ther.* 2017 Aug 28;10:4225-4238. doi: 10.2147/OTT.S137107. eCollection 2017. IF 2.612
23. Jurj A, Braicu C, Pop LA, Tomuleasa C, Gherman CD, Berindan-Neagoe I. The new era of nanotechnology, an alternative to change cancer treatment. *Drug Des Devel Ther.* 2017 Sep 27;11:2871-2890. doi: 10.2147/DDDT.S142337. eCollection 2017. Review. IF 3.028
24. Boca S, Berce C, Jurj A, Petrushev B, Pop L, Gafencu GA, Selicean S, Moisoiu V, Temian D, Micu WT, Astilean S, Braicu C, Tomuleasa C, Berindan-Neagoe I. Ruxolitinib-conjugated gold nanoparticles for topical administration: An alternative for treating alopecia? *Med Hypotheses.* 2017 Nov;109:42-45. doi: 10.1016/j.mehy.2017.09.023. Epub 2017 Sep 27. IF 1.152
25. Pop LA, Cojocneanu-Petric RM, Pileczki V, Morar-Bolba G, Irimie A, Lazar V, Lombardo C, Paradiso A, Berindan-Neagoe I. Genetic alterations in sporadic triple negative breast cancer. *Breast.* 2017 Dec 1;38:30-38. doi: 10.1016/j.breast.2017.11.006. IF 2.381
26. Gulei D, Magdo L, Jurj A, Raduly L, Cojocneanu-Petric R, Moldovan A, Moldovan C, Florea A, Pasca S, Pop LA, Moisoiu V, Budisan L, Pop-Bica C, Ciocan C, Buiga R, Muresan MS, Stiufiuc R, Ionescu C, Berindan-Neagoe I. The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression. *Cell Death Dis.* 2018 Jan 19;9(2):66. doi: 10.1038/s41419-017-0102-8. IF. 6.187
27. Tomuleasa C, Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, Micu WT, Moisoiu V, Osan C, Constantinescu C, Pasca S, Jurj A, Pop L, Berindan-Neagoe I, Dima D, Kitano S. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. *Front Immunol.* 2018 Feb 19;9:239. doi: 10.3389/fimmu.2018.00239. eCollection 2018. Review. IF 6.429
28. Tomuleasa C, Selicean C, Cismas S, Jurj A, Marian M, Dima D, Pasca S, Petrushev B, Moisoiu V, Micu WT, Vischer A, Arifeen K, Selicean S, Zdrenghea M, Bumbea H, Tanase A, Grewal R, Pop L, Aanei C, Berindan-

- Neagoe I. Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches. *Crit Rev Clin Lab Sci*. 2018 Aug;55(5):329-345. doi: 10.1080/10408363.2018.1463508. Epub 2018 May 25. Review. IF 6.481
29. Cismaru CA, Pop L, Berindan-Neagoe I. Incognito: Are Microchimeric Fetal Stem Cells that Cross Placental Barrier Real Emissaries of Peace? *Stem Cell Rev*. 2018 Oct;14(5):632-641. doi: 10.1007/s12015-018-9834-9. Review. IF 2.967
30. Chira S, Raduly L, Braicu C, Jurj A, Cojocneanu-Petric R, Pop L, Pileczki V, Ionescu C, Berindan-Neagoe I. Premature senescence activation in DLD-1 colorectal cancer cells through adjuvant therapy to induce a miRNA profile modulating cellular death. *Exp Ther Med*. 2018 Aug;16(2):1241-1249. doi: 10.3892/etm.2018.6324. Epub 2018 Jun 19. IF 1.410
31. Jurj A, Pop L, Petrushev B, Pasca S, Dima D, Frinc I, Deak D, Desmirean M, Trifa A, Fetica B, Gafencu G, Selicean S, Moisoiu V, Micu WT, Berce C, Sacu A, Moldovan A, Colita A, Bumbea H, Tanase A, Dascalescu A, Zdrenghea M, Stiufiuc R, Leopold N, Tetean R, Burzo E, Tomuleasa C, Berindan-Neagoe I. Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome. *Crit Rev Clin Lab Sci*. 2018 Nov;55(7):501-515. doi: 10.1080/10408363.2018.1499707. Epub 2018 Sep 21. IF 6.481
32. Temian DC, Pop LA, Irimie AI, Berindan-Neagoe I. The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge. *J Breast Cancer*. 2018 Sep;21(3):233-243. doi: 10.4048/jbc.2018.21.e41. Epub 2018 Sep 20. Review IF 2.456
33. Braicu C, Raduly L, Morar-Bolba G, Cojocneanu R, Jurj A, Pop LA, Pileczki V, Ciocan C, Moldovan A, Irimie A, Eniu A, Achimas-Cadariu P, Paradiso A, Berindan-Neagoe I. Aberrant miRNAs expressed in HER-2 negative breast cancers patient. *J Exp Clin Cancer Res*. 2018 Oct 20;37(1):257. doi: 10.1186/s13046-018-0920-2. IF 6.217
34. Zaharie F, Pop LA, Petrushev B, Jurj A, Muresan MS, Eniu D, Fetica B, Petkov B, Pasca S, Piciu D, Rus I, Deak D, Dima D, Desmirean MS, Tomuleasa C, Berindan-Neagoe I. Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient. *Histol Histopathol*. 2018 Nov 23:18067. doi: 10.14670/HH-18-067. [Epub ahead of print] IF 2.025
35. Raluca Maniu D, Blag C, Popa G, Bota M, Vlad C, Cainap C, Balacescu O, Pop L, Cainap SS. The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia. *J BUON*. 2018 Dec;23(7):122-131. IF 1.344

Total Citations: 160

Hirsch index: 7

<b>BDI Articles</b>	<p>► Petric RC, <u>Pop LA</u>, Jurj A, Raduly L, Dumitrascu D, Dragos N, Neagoe IB. Next generation sequencing applications for breast cancer research. Clujul Med. 2015;88(3):278-87. doi: 10.15386/cjmed-486. Review.</p> <p>► Lucan C, <u>Pop LA</u>, Florian A, Pileczki V, Petrushev B, Dima D, Frinc I, Berindan-Neagoe I, Irimie A, Berce C, Florian IS, Bojan A, Tomuleasa C. HLA Genotyping using Next Generation Sequencing. Rom J Intern Med. 2016 Apr-Jun;54(2):98-104. doi: 10.1515/rjim-2016-0019.</p>
<b>National Books</b>	
<b>Chapters</b>	<p>➤ Ioana Berindan-Neagoe, Cornelia Braicu, Roxana Cojocneanu-Petric, Carolina Constantin, Maria Dobre, Radu-Ionut Huica, <u>Laura Isprava</u>, Gina Manda, Elod Nagy, Ionela Neagoe, Monica Neagu, Aurora Salageanu, Mihaela Surcel, Catalin Tucureanu, Cornel Ursaciuc, Mihaela Zlei- <i>Ghid de Organizare a Laboratorului de Imunologie</i>, sub redatia Prof. Dr. Victor Cristea. Editura Medicala Universitara "Iuliu Hatieganu", Cluj-Napoca, 2013 ISBN 978-973-693-550-3. Capitolul: Imunologie si Imunogenetica, Subcapitolul: Secventierea de noua generatie in relatie cu imonogenetica,</p> <p>➤ Valentina Pileczki, Laura Pop, Monica Mihaela Marta, Delia Dima, Ioana Berindan-Neagoe, Molecular Biology in AML and CLL pg.189-206, chapter of the book Nanopharmacology in leukemia chemotherapy edited by Andrei Cucuianu, Ciprian Tomuleasa, Simion Astilean, Anca Boja, Cristian Berce, Emmet McCormack, Editura Scoala Ardeleana ; Bucuresti, EIKON 2015, ISBN: 978-606-8699-74-5.</p> <p>➤ Ciprian Tomuleasa, Bobe Petrushev, <u>Laura Pop</u>, Mariana Patiu, Anca Bojan, Ioana Berindan-Neagoe. Terapii bazate pe anticorpi monoclonali chapter in book Chimioterapie Hematologică autori Ciprian Tomuleasa, Mariana Patiu, Anca Bojan, Mihnea Zdrengea, Cristian Berce, Ioana Frinc, Bobe Petroshev, Delia Dima, George Călin, Alina Tănase, Ștefan Ciurea. Editura Școala Ardeleană; București, EIKON 2016 ISBN: 978-606-8770-30-7</p> <p>➤ Delia Dima, Mariana Patiu, Anca Bojan, Ciprian Tomuleasa, Emmanuel Akin Abayomi, Cristian Berce, Ioana Berindan-Neagoe, Mariana Chitic, Anca Colita, Ioana Frinc, Ravnit Grewal, Cristian Moldovan, Claudia Nicorici-Fekete, Mohamed Noor, Bobe Petrushev, Andra Piciu, Doina Piciu, <u>Laura Pop</u>, Ana Maria Rosu, Cristina Selician, Alina Tanase, Adrian Trifa, Florin Zaharie, Mihai Muresan, Hematologia in imagini, Editura Eikon, 2016 ISBN 1978-606-8770-69-7. Chapter Metode de diagnostic Modern.</p> <p>➤ Ciprian Tomuleasa, Delia Dima, Adrian Trifa-Leucemia cronică- De la terapia cu inhibitori cu tirozin kinaze la transplant- Chapter- Aplicatiile secventierii de noua generatie in leucemia cronică mieloidă-pp36-42, Editura Scoala Ardeleana-Cluj-Napoca- Eikon Bucuresti- 2016, ISBN-978-606-8770-98-7.</p>
<b>International Books</b>	
<b>Chapters</b>	<p>➤ <u>LA Pop</u>, JA López-Guerrero, I Berindan-Neagoe An Overview of Omics Technologies for Renal Cell Carcinoma Diagnosis and Profiling chapter in book Renal Cell Carcinoma, SMGoup, Dover, USA, ISBN: 978-1-944685-66-9, 2016</p>
<b>Research projects</b>	
<b>Member</b>	<p>➤ POSCCE 2010 nr. 709/12683 Contract 228/06.08.2010 Clinical and Economical Impact of the transcriptomic and proteomic molecular profile</p>

identification in the neoadjuvant therapy of triple negative breast cancer”- BREASTIMPACT - August 2010- February 2014, Budget 5.916.336

- PN II contract no. 96/2012: “miRNA Analysis as possible biomarkers with a possible predictive value for the treatment of cervical cancer, in relationship with the exposure to environmental factors like arsenic, phthalate and cotinine (Cervicall-arsen-array)”, 2012-2016, Budget 600.000
- PN II contract no. 125/2012: Intelligent Systems of prediction of recurrence and progression in superficial bladder cancer based on artificial intelligence and microarray data: tumor mRNA and plasmatic microRNA-IntelUro; 2012-2016, Budget 805.438
- PN II contract no. 128/2014-“New strategies for improving cancer patient’s quality of life and survival: molecular and clinical studies of cancer genome using depleted deuterium water model- GenCanD”; 01.07.2014-30.06.2016, Budget 586.000
- PN II contract no. 196/2014: ”Modulation of pro/anticarcinogenic effect of toxic chemical agents in breast cancer multitargeted therapy-CANCERTER-p53”; 01.07.2014-30.06.2016, Budget 614.650
- PN II contract no. 137/2014- Developing a method for real-time detection and isolation of circulating tumor cells from the bloodstream of cancer patients by means of image processing and pattern recognition. (CTC VideoScop)”; 01.07.2014-30.06.2016 Budget 525.000
- PN II contract no. 193/2014-“Non-Invasive Intelligent Systems for Colorectal Cancer Diagnosis and Prognosis Based on Circulating miRNA Integrated in the Clinical Workflow -INTELCOR”; 01.07.2014-30.06.2016, Budget 375.000
- Contract ESR-14-10102/17.10.2014-“BRCA1 and BRCA2 mutation analysis in Romanian population: a study of genotype-phenotype correlation at diagnosis with prospective disease outcome and survival”. 2014-2016 Budget 472.162
- PN-II-RU-TE-2014-4-1464, CTR.307/01.10.2015, Titlul ”Țintirea căii de semnalizare TGFβ: o alternativa în terapia cancerului de sân”, 2016-2017, buget 550000 lei
- PN II RU-TE-2014-4-2830, Ctr. Nr. 376 / 01.10.2015 Polimorfismul genetic si rolul sau predictiv in chimioterapia cancerului colorectal metastatic. 01.10.2015 – 30.09.2017, buget 549.369 lei
- PN-II-RU-TE-2014-4-2951, Nr. contract finantare: 125/01.10.2015 “Inhibitia caili de semnalizare dependenta de VEGFR2 regleaza angiogeneza in Teleangiectazia Ereditara de Tip 2”, 01.01.2016-15.11.2016 Buget 550.000 lei

	<ul style="list-style-type: none"> <li>➤ ID P_40_318, contract nr. 10/01.09.2016 „Transfer de cunoștințe în aplicații clinice ale biogenomicii în oncologie și domenii conexe – BIOGENONCO” perioada 2016-2020 Buget 13.468.737,50 Lei</li> <li>➤ P_37_796. “IMPACTUL CLINIC ȘI ECONOMIC AL TERAPIILOR PERSONALIZATE ȚINTITE CU ANTI – MICROARNuri ÎN RECONVERTIREA REZISTENȚEI TUMORILOR MALIGNЕ PULMONARE CANTEMIR” – 2016-2020 Buget 8.590.872,88 Lei</li> <li>➤ ID P_37_783, Abordari genomice si microfluidice in blocarea invaziei si a metastazarii cancerului de san, cu număr de înregistrare electronica-perioada 2016-2020-Buget</li> <li>➤ Bridge Grant 2016, Contractul de Finantare nr.108/BG/2016, ID: PN-III-P2-2.1-BG-2016-0117 cu titlul „Cresterea accesului la terapii celulare prin izolarea si stocarea celulelor stem mezenchimale din placenta umana-PlaNet”, 2018</li> <li>➤ PN-III-P4-ID-PCE-2016-0795Abordarea complexa a profilului expozomic in cancerele hormono-dependente de san si prostata si influenta acestuia in genomul tumoral (Achile)-2017-2019-Budget 1.000.000</li> <li>➤ PN-III-P1-1.2-PCCDI-2017-0782, nr. 65PCCDI/2018:Abordari inovative avansate pentru medicina regenerativa predictiva (Regmed) -2018-2020</li> <li>➤ PN-III-P4-ID-PCCF-2016-0112-Nanomateriale magnetoplasmonice multifunctionale pentru aplicatii de tip point of care (NanoTEX)-2018-2021-Budget 850.000</li> </ul>
Awards	<ul style="list-style-type: none"> <li>➤ <b>PhD scholarship</b> given by de Babeș Bolyai University, Cluj-Napoca as part of the project”Studii doctorale : prin știință spre societate” Contract no. POSDRU/6/1.5/S/3/2008. Oct 2008-Oct 2011</li> <li>➤ <b>Award for special results obtained during PhD studies as scholar of the project</b> POSDRU 6/1.5/S/3-ID 5216.</li> <li>➤ <b>Postdoctoral Scholarship</b> given by the University of Medicine and Pharmacy ”Iuliu Hațieganu ” Cluj-Napoca as part of the POSDRU project „Model colaborativ instituțional pentru translarea cercetării științifice biomedicale în practica clinică - TRANSCENT”, Contract no. POSDRU/159/1.5 /S/138776- Mai 2014-Sep 2015. Project entitle „<b>Identificarea de noi mutații în cancerul de sân folosind secvențierea de nouă generație</b>”.</li> <li>➤ Participation Grant for “Precision Medicine for Cancer” 1-4 March 2015 Neumünster Abbey, Luxembourg</li> </ul>